Can patients with atrial fibrillation (AF) use steroid nasal sprays?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Yes, patients with atrial fibrillation (AF) can generally use steroid nasal sprays safely, as they have minimal systemic absorption and therefore rarely affect heart rhythm or interact with AF medications 1. Common steroid nasal sprays like fluticasone (Flonase), mometasone (Nasonex), budesonide (Rhinocort), and triamcinolone (Nasacort) are considered safe for AF patients. These medications are typically used once or twice daily, with 1-2 sprays in each nostril as directed on the packaging.

To ensure proper use, patients should:

  • Prime the spray before first use according to product instructions
  • Gently shake the bottle prior to spraying
  • Blow their nose prior to using the spray
  • Keep their head in an upright position
  • Hold the spray in the opposite hand in relation to the nostril in which the spray should be applied
  • Breathe in gently or slowly during spraying
  • Not close the opposite nostril to prevent pushing the septum to the side of the spray

It's essential for AF patients to use the lowest effective dose for the shortest duration needed to control symptoms. The safety profile relates to the localized action of these medications, as they primarily work directly on nasal tissues to reduce inflammation without significantly entering the bloodstream 1. However, patients should still inform their cardiologist about all medications they're using, including over-the-counter nasal sprays, to ensure there are no specific contraindications based on their individual cardiac condition or medication regimen. The most recent guidelines for managing atrial fibrillation, such as those from the European Society of Cardiology 1, do not specifically address the use of steroid nasal sprays but emphasize the importance of managing comorbidities and avoiding interactions with other medications.

From the Research

Considerations for Patients with Atrial Fibrillation

When considering the use of steroid nasal sprays for patients with atrial fibrillation (AF), several factors must be taken into account.

  • The potential for steroid nasal sprays to induce or exacerbate atrial fibrillation, as suggested by a case report where fluticasone propionate was associated with the development of paroxysmal AF in a 15-year-old boy 2.
  • The management and treatment of AF, which includes drug therapy, catheter ablation, and other procedures, does not directly address the use of steroid nasal sprays 3, 4.
  • The efficacy and safety of fluticasone propionate aqueous nasal spray for the treatment of seasonal allergic rhinitis, which has been shown to improve nasal symptoms when used as needed 5.
  • The primary concern for patients with AF is the prevention of thromboembolic events, for which anticoagulation therapy is the mainstay of treatment, and the use of steroid nasal sprays is not directly relevant to this aspect of AF management 6.

Potential Risks and Interactions

  • There is limited evidence directly linking the use of steroid nasal sprays with the exacerbation or induction of AF, but the case report suggests a possible relationship between high doses of inhaled corticosteroids and adverse cardiovascular reactions, including AF 2.
  • Patients with AF should be aware of the potential for interactions between their heart condition and any medications they are taking, including steroid nasal sprays, although the current literature does not provide comprehensive guidance on this specific interaction.
  • The decision to use steroid nasal sprays in patients with AF should be made on a case-by-case basis, considering the individual's overall health status, the severity of their AF, and the potential benefits and risks of the treatment.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Rhythm control in atrial fibrillation.

Lancet (London, England), 2016

Research

Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn).

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.